Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 28;17(10):3747–3756. doi: 10.1080/21645515.2021.1932217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Evolution of anti-VZV antibody GMCs (lines) and the number of participants (table) in the Active Control group (per-protocol cohort for efficacy)

Case before previous visit, varicella case confirmed before blood sampling preceding the reference point; Case since previous visit, varicella case confirmed between previous and reference blood sampling; No case, no varicella case detected until the reference point (data for all of these participants and for a subset excluding the seronegative participants is shown); VZV, varicella-zoster virus; GMC, geometric mean concentration in milli-international units per mL (mIU/mL); 95% CI, 95% confidence interval; Follow-up timepoints, blood samples collected at indicated study visits after the second vaccine dose; Y1–Y10, post-vaccination blood samples obtained at year one, two, four, six, eight, and ten of follow-up.